Vertex rises after earnings as it raises its sales outlook, while acquisition costs weigh on profit
Earnings results
- EPS comparison not verified
Actual: $4.76 (adjusted)
- Revenue comparison not verified
Actual: $3.4408 (reported, billions)
- Guidance
Raised FY2026 revenue to $13.15–$13.25 billion from $13.1–$13.2 billion; increased adjusted operating-expense guidance to approximately $6.0 billion.
Earnings and the stock move
Vertex’s November 2 earnings release raised full-year revenue guidance by $50 million at the midpoint and showed continued growth in medicines beyond cystic fibrosis. The report also increased operating-expense guidance as the company integrates Crinetics and prepares a potential kidney-medicine launch. Shares rose after close following the release; the higher sales outlook should be considered alongside the acquisition’s costs and pending regulatory decisions.
Q3 2026 ended September 30 earnings recap
Vertex rose 4.0% after hours on November 2, 2026, following earnings and a higher full-year sales outlook. Acquisition costs remain an important counterweight to revenue growth.
- Vertex raised its full-year revenue range to $13.15–$13.25 billion from $13.1–$13.2 billion. The midpoint increased by $50 million, with the acquired PALSONIFY medicine now contributing to sales.
- Third-quarter revenue reached $3.44 billion, up 12% from a year earlier. Cystic-fibrosis medicines remained the core business while newer treatments added growth.
- Adjusted EPS, or profit per share, was $4.76; GAAP EPS was $2.56. Acquisition-related costs help explain why accounting profit was much lower than adjusted profit.
- CASGEVY gene-therapy revenue reached $99 million and JOURNAVX pain-medicine revenue reached $58 million. These launches help broaden the business beyond cystic fibrosis.
- Vertex also raised its adjusted operating-expense outlook to about $6 billion. Investors need to weigh the added sales against integration, research and launch spending.
- The next major scheduled decision is the FDA’s November 30 target date for povetacicept in a kidney disease. The medicine is still under review for this use.
The November 2 chart shows the completed regular session; the earnings gain came afterward. Watch launch progress, spending and the regulatory decision, with sharp price swings still possible.
Financials and technicals
Charts through Nov 2, 2026. The session move above may reflect later news.
Technical setup and risks
Vertex closed the November 2 regular session at $553.15, above its 20-day and 50-day averages. The after-close quote rose above the recent $564–$569 high area. Holding above that area in the next regular session would strengthen the breakout; falling below $553 would erase the initial gain. Use closing prices and volume for confirmation; levels are not guarantees.
After-hours move is measured versus the same-day regular close AI-assisted research with source and calculation checks. Prices may be delayed. Technical charts use the stated completed session, which can precede the quoted intraday move. Educational information; investing involves risk.